On September 7, 2022 Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported that Douglas E. Onsi, President and Chief Executive Officer, will participate in a fireside chat at the Baird 2022 Global Healthcare Conference, being held in New York on September 13-14, 2022 (Press release, Leap Therapeutics, SEP 7, 2022, View Sourcenews-releases/news-release-details/leap-therapeutics-participate-baird-2022-global-healthcare" target="_blank" title="View Sourcenews-releases/news-release-details/leap-therapeutics-participate-baird-2022-global-healthcare" rel="nofollow">View Source [SID1234619176]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The fireside chat will be webcast live and may be accessed on the Investors page of the company’s website at View Source, where a replay of the event will also be available for a limited time.

On September 7, 2022 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, reported that Rick Pauls, its President and CEO will be participating at Lake Street Capital Market’s 6th Annual Best Ideas Growth (BIG6) Conference in New York, on September 14, 2022 (Press release, DiaMedica, SEP 7, 2022, View Source [SID1234619174]). Management will conduct one-on-one meetings with investors during the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To receive additional information or to schedule a one-on-one meeting, please contact your Lake Street Capital Markets representative.

On September 7, 2022 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022 (Press release, Moleculin, SEP 7, 2022, https://moleculin.com/moleculin-to-present-at-the-h-c-wainwright-24th-annual-global-investment-conference/ [SID1234619172]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.

A video webcast of the presentation will be available for viewing on-demand through the H.C. Wainwright conference platform beginning Monday, September 12 at 7:00 AM ET for 30-days to those registered for the event.

On September 7, 2022 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, reported that Stephen R. Brady, chief executive officer of Tempest, will present at the H.C. Wainwright 24th Annual Global Investment Conference (Press release, Tempest Therapeutics, SEP 7, 2022, View Source [SID1234619171]). The company presentation will be available for on-demand viewing Monday, September 12, 2022, at 7:00 a.m. ET on the investor section of the Tempest website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 7, 2022 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that company management will participate in the following upcoming investor conferences in September (Press release, Jounce Therapeutics, SEP 7, 2022, View Source [SID1234619170]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright 24th Annual Global Investment Conference: Fireside chat on Monday, September 12, 2022 at 10:00 a.m. ET in New York, NY.

Cantor Oncology, Hematology & HemeOnc Conference: Panel titled, "Tackling the Tumor Microenvironment and Further Arming the Immune System" on Wednesday, September 28, 2022 at 2:35 p.m. ET in New York, NY.
A webcast of the presentations will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.